ArticleNeuroscience2016
Role of TrkB in the anxiolytic-like and antidepressant-like effects of vagal nerve stimulation: Comparison with desipramine.
Article in Neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Transcranial Stimulation Methods in the Treatment of MDD Patients-The Role of the Neurotrophin System.International journal of molecular sciences · 2025Review
- Transcutaneous Auricular Vagus Nerve Stimulation Restores Cognitive Impairment in Morphine-Withdrawn Rats: Role of BDNF and Glial Cells in the Hippocampus.Addiction biology · 2025Article
- Vagus nerve stimulation rescues impaired fear extinction and social interaction in a rat model of autism spectrum disorder.Journal of affective disorders · 2025Article
- Neuron-Microglia Interaction is Involved in Anti-inflammatory Response by Vagus Nerve Stimulation in the Prefrontal Cortex of Rats Injected with Polyinosinic:Polycytidylic Acid.Molecular neurobiology · 2024Article
- The gut-brain axis and cognitive control: A role for the vagus nerve.Seminars in cell & developmental biology · 2024Review
- Mechanisms of vagus nerve stimulation for the treatment of neurodevelopmental disorders: a focus on microglia and neuroinflammation.Frontiers in neuroscience · 2024Review
- Vagus nerve stimulation: a physical therapy with promising potential for central nervous system disorders.Frontiers in neurology · 2024Review
- Exploring the potential of vagus nerve stimulation in treating brain diseases: a review of immunologic benefits and neuroprotective efficacy.European journal of medical research · 2023Review
- Review
- Repeated vagus nerve stimulation produces anxiolytic effects via upregulation of AMPAR function in centrolateral amygdala of male rats.Neurobiology of stress · 2022Article
- Vagus Nerve Stimulation as a Treatment for Fear and Anxiety in Individuals with Autism Spectrum Disorder.Journal of psychiatry and brain science · 2022Article
- Vagus nerve stimulation promotes extinction generalization across sensory modalities.Neurobiology of learning and memory · 2021Article
- Peripheral effects of vagus nerve stimulation on anxiety and extinction of conditioned fear in rats.Learning & memory (Cold Spring Harbor, N.Y.) · 2019Article
- Therapeutic Potential of the Microbiome in the Treatment of Neuropsychiatric Disorders.Medical sciences (Basel, Switzerland) · 2019Review
- Vagus nerve stimulation as a tool for enhancing extinction in exposure-based therapies.Psychopharmacology · 2019Review
- Vagal Nerve Stimulation for Treatment-Resistant Depression.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Vagus nerve stimulation promotes generalization of conditioned fear extinction and reduces anxiety in rats.Brain stimulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
A current hypothesis regarding the mechanism of antidepressant (AD) action suggests the involvement of brain-derived neurotrophic factor (BDNF). Consistent with this hypothesis, the receptor for BDNF (and neurotrophin 4/5 (NT-4/5)), Tropomyosin-related kinase B (TrkB), is activated in rodents by treatment with classical AD drugs. Vagal nerve stimulation (VNS), a therapy for treatment resistant depression (TRD), also activates TrkB in rodents. However, the role of this receptor in the therapeutic effects of VNS is unclear. In the current study, the involvement of TrkB in the effects of VNS was investigated in rats using its inhibitor, K252a. Anxiolytic-like and AD-like effects were analyzed using the novelty suppressed feeding test (NSFT) and forced swim test (FST), respectively. K252a blocked the anxiolytic-like effect of chronic VNS treatment and the AD-like effect of acute VNS treatment. By contrast, blocking TrkB did not prevent either the anxiolytic-like or AD-like effect of chronic treatment with desipramine (DMI), a selective noradrenergic reuptake inhibitor; it did, however, block the acute effect of DMI in the FST. To examine whether the activation of TrkB caused by either VNS or DMI is ligand-dependent, use was made of TrkB-Fc, a molecular scavenger for ligands of TrkB. Intraventricular administration of TrkB-Fc blocked the acute activation of TrkB induced by either treatment, indicating that treatment-induced activation of this receptor is ligand-dependent. The behavioral results highlight differences in the involvement of TrkB in the chronic effects of an AD drug and a stimulation therapy as well as its role in acute versus chronic effects of DMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.